Marinomed Biotech AG Reports Positive Clinical Results for Unique Carragelose Eye Drops

Marinomed Biotech AG has announced positive clinical trial results for their new Carragelose eye drops. Designed to address dry eye syndrome, these drops improved symptoms by 54% in patients with mild to moderate conditions.

The study, conducted in Spain, involved 28 patients subjected to adverse environmental conditions. The trial lasted 28 days, with participants applying one drop per eye three times daily.

Alongside this significant improvement, the eye drops were well tolerated and showed a marked reduction in the Ocular Surface Disease Index (OSDI). The strongest effects were observed on pain and blurred vision.

The eye drops hold a valid Medical Device Directive (MDD) certificate and are in the transition phase for the new Medical Device Regulation (MDR), with a planned launch in 2024. The product is part of Marinomed's expanding Carragelose portfolio, which also targets allergies and viral respiratory infections.